Additionally, the long‐acting agonist for the GLP‐1 receptor, such as NLY01, prevented dopaminergic loss and behavioral abnormalities and inhibited astrocyte conversion to the toxic A1 phenotype, a key driver of PD inflammation [115]. This evidence concerns the gene GLP1R and Parkinson disease.